Inclusion Criteria:

          -  Pathologically verified stage IV gastric carcinoma, nasopharyngeal carcinoma and
             lymphoma with measurable lesions (At least one measurable lesion or the immunotherapy)

          -  Pathologically verified as EBV positive malignancies

          -  Human leukocyte antigen (HLA) genotypes: HLA-A02, HLA-A24 or HLA-A11 genotypes

          -  Progressed after standard treatment or the patients refused to accept the standard
             treatment

          -  Performance score: 0-1

          -  Expected life span: >= 3 months

          -  Toxicities from prior treatment has resolved. Washout period is 1 months

          -  Major organs function normally

          -  Women at pregnant ages should be under contraception

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Patients with possible drug allergy of immunotherapy

          -  Patients with active bacterial or fungal infections

          -  Coagulopathy, or ongoing thrombolytics and/or anticoagulation

          -  Blood-borne infectious disease, e.g. hepatitis B, hepatitis C and HIV

          -  History of coronary artery disease, asthma, or vascular disease or other disease
             inappropriate for treatment deemed by treating physician

          -  With other tumors except for in situ cervical cancer, treated squamous cell carcinoma
             and bladder cancer (Ta and TIS) or other malignancies that have been treated with
             radical therapy (at least for 5 years before the enrollment)

          -  With other immune diseases, or chronic use of immunosuppressants or steroids

          -  Pregnant and lactating women

          -  Compliance cannot be expected

          -  Other conditions requiring exclusion deemed by physician